Merck & Co. Inc. (MRK) News

Merck & Co. Inc. (MRK): $103.90

-0.33 (-0.32%)

POWR Rating

Component Grades













Filter MRK News Items

MRK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MRK News Highlights

  • MRK's 30 day story count now stands at 22.
  • Over the past 16 days, the trend for MRK's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • LI, LUNG and VTRS are the most mentioned tickers in articles about MRK.

Latest MRK News From Around the Web

Below are the latest news stories about MERCK & CO INC that investors may wish to consider to help them evaluate MRK as an investment opportunity.

Amplifying the Power of Women in Chemistry

Merck & Co., Inc.

Yahoo | March 22, 2023

The Zacks Analyst Blog Highlights Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton

Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton are part of the Zacks top Analyst Blog.

Yahoo | March 22, 2023

7 Healthcare Stocks to Buy for Long-Term Growth and Stability

These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio

Muslim Farooque on InvestorPlace | March 21, 2023

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Merck (MRK) closed at $105.54, marking a -0.29% move from the previous day.

Yahoo | March 21, 2023

Top Research Reports for Merck, Intel & MercadoLibre

Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Intel Corporation (INTC) and MercadoLibre, Inc. (MELI).

Yahoo | March 21, 2023

Merck, Viatris settle patent dispute over Januvia

  • Merck (NYSE:MRK) and Mylan, the latter now part of Viatris (NASDAQ:VTRS), are asking a judge to stay an appeal as the two parties have come to a settlement over a patent dispute on the diabetes drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin).
  • In a March 16 joint filing, the companies said that a 60-day stay of the appeal is needed to hammer out the settlement in preparation for an amended fi...

    Seeking Alpha | March 20, 2023

7 Defensive Stocks to Buy During This Chaotic Spell

With turmoil erupting on Wall Street over the banking sector crisis, investors should turn to reliable defensive stocks to buy.

Josh Enomoto on InvestorPlace | March 20, 2023

Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?

Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.

Yahoo | March 20, 2023

Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study

Data from a mid-stage study showed that Merck's (MRK) MK-7684A did not improve progression-free survival as a potential treatment for patients with metastatic non-small cell lung cancer.

Yahoo | March 17, 2023

Merck's Keytruda Combo Therapy Less Effective Than Chemo In Lung Cancer Patients, Data Shows Merck & Co Inc's (NYSE: MRK) MK-7684A failed the open-label portion of a Phase 2 study KeyVibe-002 trial. MK-7684A, a combination of Keytruda (pembrolizumab) and in-house anti-TIGIT compound vibostolimab, did not improve patients' progression-free survival compared to chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) with progressive disease after treatment wit

Yahoo | March 17, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7421 seconds.